Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients and whether or not Tarceva (erlotinib) would prevent disease recurrence. February 2014.
[powerpress]
Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.
[powerpress]
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute discusses whether or not patients on targeted therapies, such as EGFR inhibitors, should stay on those therapies after their cancers begin to grow again. February 2014.
[powerpress]
Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. February 2014.
[powerpress]
Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.
[powerpress]
This is a slide presentation I did last week at a local conference, describing the steady, incremental improvements in survival with advanced/metastatic non-small cell lung cancer (NSCLC) that have occurred over the past 10-15 years.
Dr. Cathy Pietanza of Memorial Sloan Kettering explains how small cell lung cancer and non-small cell lung cancer are differentiated. February 2014.
Dr. Charles Rudin of Memorial Sloan Kettering talks about RAF and other genetic mutations that play a role in the growth of lung cancer. February 2014.
[powerpress]
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will allow oncologists to test patients' lung tumors without invasive biopsies. February 2014.
[powerpress]
Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014.
[powerpress]
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock